In mid-September 2015, a second case management order and two new pretrial orders were issued in the Xarelto multidistrict litigation (“MDL”), centralized in the Eastern District of Louisiana. The case management order issued identifies the schedule and procedures for the Xarelto bellwether trials, set to begin February 2017. The two orders issued are Pretrial Order 15A, which requires plaintiffs and defendants to either refrain from sending emails, text, voice, and instant messages relating to Xarelto or to preserve and transcribe any such messages initiated; and Pretrial Order 21, which establishes document production protocol from Xarelto’s manufacturers Bayer and Janssen Pharmaceuticals.
The Xarelto MDL was formed in December 2014 after roughly 550 cases were filed against Bayer and Janssen alleging similar claims that the drugmakers touted Xarelto as being a safe alternative to competitor blood thinner warfarin while downplaying the anticoagulant’s high risk for serious and potentially fatal bleeding events.
The law firm of Grant & Eisenhofer is involved in the Bellwether Selection Committee and is also co-leading the Law & Briefing Committee of the Xarelto MDL. G&E filed several complaints on behalf of Xarelto patients and families of lost loved ones who suffered from Bayer and Janssen’s alleged negligence. If you or a loved one experienced complications from taking the drug Xarelto, please call us at 888-207-0382 for a confidential evaluation of your potential claim.